{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000016","form_type":"8-K/A","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.516887+00:00","generated_at":"2026-06-27T17:53:56.938151+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Castle Biosciences acquires Cernostics for up to $30M upfront plus $50M earnout","bullets":["Up-front consideration $30M (cash or cash/stock mix); earnouts up to $50M based on 2022 commercial milestones.","Cernostics 9M2021 revenue $469K, net loss $2.8M; 2020 revenue $141K, net loss $2.6M.","Cernostics' TissueCypher Barrett's Esophagus Assay added to Castle's diagnostics portfolio.","Transaction closed December 2021; amendment files required financial statements."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000016","json":"https://secwatch.observer/filing/0001447362-22-000016.json","markdown":"https://secwatch.observer/filing/0001447362-22-000016.md","text":"https://secwatch.observer/filing/0001447362-22-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000016/0001447362-22-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000016/cstl-20211202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:53:56.938151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}